Publications | Professor Shudong Wang & Team

Small-Molecule Inhibitors of Tankyrases as Prospective Therapeutics for Cancer

Mingfeng Yu, Yuchao Yang, Matthew Sykes, and Shudong Wang
Journal of Medicinal Chemistry, 2022

DOI: 10.1021/acs.jmedchem.1c02139

US FDA Approved Small-Molecule Kinase Inhibitors for Cancer Therapy

Abraham, D.J., Yu, M., Tadesse, S. and Wang, S. (2022). US FDA-Approved Small-Molecule Kinase Inhibitors for Cancer Therapy. In Burger’s Medicinal Chemistry and Drug Discovery, D.J. Abraham (Ed.). https://doi.org/10.1002/0471266949.bmc214.pub2

An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia

Anshabo AT, Bantie L, Diab S, Lenjisa J, Kebede A, Long Y, Heinemann G, Karanjia J, Noll B, Basnet SKC, Li M, Milne R, Albrecht H, Wang S. Cancers. 2022; 14(5):1113. https://doi.org/10.3390/cancers14051113

Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation

Mingfeng Yu, Yi Long, Yuchao Yang, Manjun Li, Theodosia Teo, Benjamin Noll, Stephen Philip, Shudong Wang. European Journal of Medicinal Chemistry 218 (2021) 113391, https://doi.org/10.1016/j.ejmech.2021.113391.

Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations

Yi Long, Mingfeng Yu, Aleksandra M. Ochnik, Jasmine D. Karanjia, Sunita KC. Basnet, Alemwork A. Kebede, Lianmeng Kou, Shudong Wang,
European Journal of Medicinal Chemistry, 213 (2021) 113215,

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents

Anshabo AT, Milne R, Wang S and Albrecht H (2021) Frontiers in Oncology. 11:678559.
doi: 10.3389/fonc.2021.678559

A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer

Laychiluh Bantie, Solomon Tadesse, Jimma Likisa, Mingfeng Yu, Benjamin Noll, Gary Heinemann, Noor A. Lokman, Carmela Ricciardelli, Martin K. Oehler, Andrew Beck, Rupal Pradhan, Robert Milne, Hugo Albrecht, Shudong Wang, Gynecologic Oncology, Volume 163, Issue 1, October 2021, Pages 215

https://doi.org/10.1016/j.ygyno.2020.09.012

Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation

Mingfeng Yu, Theodosia Teo, Yuchao Yang, Manjun Li, Yi Long, Stephen Philip, Benjamin Noll, Gary K. Heinemann, Sarah Diab, Preethi Eldi, Laychiluh Mekonnen, Abel T. Anshabo, Muhammed H. Rahaman, Robert Milne, John D. Hayball, Shudong Wang,
European Journal of Medicinal Chemistry, 214 (2021) 113248,

CDK12: a potential therapeutic target in cancer

Fatemeh Emadi, Theodosia Teo, Muhammed H. Rahaman, Shudong Wang
Drug Discovery Today, 2020 25 (12), 2257-2267

CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?

Sarah Diab, Mingfeng Yu, and Shudong Wang
Journal of Medicinal Chemistry 2020 63 (14), 7458-7474

Targeting CDK2 in cancer: challenges and opportunities for therapy

Tadesse S, Anshabo AT, Portman N, Lim E, Tilley W, Caldon CE, Wang S, Drug Discov Today. 2020 Feb;25(2):406-413. doi: 10.1016/j.drudis.2019.12.001.

Targeting CDK9 for treatment of colorectal cancer

Rahaman, M.H., Lam, F., Zhong, L., Teo, T., Adams, J., Yu, M., Milne, R.W., Pepper, C., Lokman, N.A., Ricciardelli, C., Oehler, M.K. and Wang, S. (2019). Mol Oncol, 13: 2178-2193. https://doi.org/10.1002/1878-0261.12559

CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia

Rahaman, M.H., Yu, Y., Zhong, L. et al. Invest New Drugs 37, 625–635 (2019).

https://doi.org/10.1007/s10637-018-0661-2

Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update

Solomon Tadesse, Elizabeth C. Caldon, Wayne Tilley, and Shudong Wang
Journal of Medicinal Chemistry 2019 62 (9), 4233-4251
DOI: 10.1021/acs.jmedchem.8b01469

Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?

Stephen Philip, Malika Kumarasiri, Theodosia Teo, Mingfeng Yu, and Shudong Wang
Journal of Medicinal Chemistry 2018 61 (12), 5073-5092

DOI: 10.1021/acs.jmedchem.7b00901

Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents

Tadesse, S.Bantie, L.Tomusange, K.Yu, M.Islam, S.Bykovska, N.Noll, B.Zhu, G.Li, P.Lam, F.Kumarasiri, M.Milne, R., and Wang, S. (2018Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agentsBritish Journal of Pharmacology1752399– 2413. doi: 10.1111/bph.13974.

In Search of Novel CDK8 Inhibitors by Virtual Screening

Malika Kumarasiri, Theodosia Teo, Mingfeng Yu, Stephen Philip, Sunita K. C. Basnet, Hugo Albrecht, Matthew J. Sykes, Peng Wang, and Shudong Wang
Journal of Chemical Information and Modeling 2017 57 (3), 413-41

DOI: 10.1021/acs.jcim.6b00711

Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells

Shengda Cao, Yingyi Yu, Shangren Chen, Dapeng Lei, Shudong Wang, Xinliang Pan, Jun Peng, Biochemical and Biophysical Research Communications, Volume 482, Issue 4, 2017, Pages 536-541,
https://doi.org/10.1016/j.bbrc.2016.11.049.

Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation

Solomon Tadesse, Mingfeng Yu, Laychiluh B. Mekonnen, Frankie Lam, Saiful Islam, Khamis Tomusange, Muhammed H. Rahaman, Benjamin Noll, Sunita K. C. Basnet, Theodosia Teo, Hugo Albrecht, Robert Milne, and Shudong Wang
Journal of Medicinal Chemistry 2017 60 (5), 1892-1915
DOI: 10.1021/acs.jmedchem.6b01670

A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors

Solomon Tadesse, Ge Zhu, Laychiluh B Mekonnen, Jimma L Lenjisa, Mingfeng Yu, Michael P Brown, and Shudong Wang
Future Medicinal Chemistry 2017 9:13, 1495-1506

https://doi.org/10.4155/fmc-2017-0076